164 related articles for article (PubMed ID: 33607068)
1. DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression.
Zheng Q; Gu X; Yang Q; Chu Q; Dai Y; Chen Z
Clin Chim Acta; 2021 Jun; 517():1-8. PubMed ID: 33607068
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract][Full Text] [Related]
3. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer.
Liang Y; Zhang CD; Zhang C; Dai DQ
Gastric Cancer; 2020 Mar; 23(2):212-227. PubMed ID: 31463827
[TBL] [Abstract][Full Text] [Related]
4. DLX6-AS1: a putative lncRNA candidate in multiple human cancers.
Sheykhhasan M; Ahmadyousefi Y; Seyedebrahimi R; Tanzadehpanah H; Manoochehri H; Dama P; Hosseini NF; Akbari M; Eslami Farsani M
Expert Rev Mol Med; 2021 Nov; 23():e17. PubMed ID: 34823630
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.
Li D; Tang X; Li M; Zheng Y
J Cell Biochem; 2019 Aug; 120(8):12290-12299. PubMed ID: 30805988
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1.
Li X; Zhang H; Wu X
Gene; 2019 Feb; 686():1-7. PubMed ID: 30366080
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.
Wu DM; Zheng ZH; Zhang YB; Fan SH; Zhang ZF; Wang YJ; Zheng YL; Lu J
J Exp Clin Cancer Res; 2019 Jun; 38(1):237. PubMed ID: 31171015
[TBL] [Abstract][Full Text] [Related]
9. LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis.
Du C; Wang Y; Zhang Y; Zhang J; Zhang L; Li J
Cell Transplant; 2020; 29():963689720929983. PubMed ID: 32686982
[TBL] [Abstract][Full Text] [Related]
10. A Peptide Encoded by a Long Non-Coding RNA DLX6-AS1 Facilitates Cell Proliferation, Migration, and Invasion by Activating the wnt/β-Catenin Signaling Pathway in Non-Small-Cell Lung Cancer Cell.
Xu X; Zhang Y; Wang M; Zhang X; Jiang W; Wu S; Ti X
Crit Rev Eukaryot Gene Expr; 2022; 32(8):43-53. PubMed ID: 36017915
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region.
Zhao H; Xu Q
J Cell Mol Med; 2020 Nov; 24(21):12572-12584. PubMed ID: 32951317
[TBL] [Abstract][Full Text] [Related]
12. DLX6-AS1 accelerates cell proliferation through regulating miR-497-5p/SNCG pathway in prostate cancer.
Zhu X; Ma X; Zhao S; Cao Z
Environ Toxicol; 2021 Mar; 36(3):308-319. PubMed ID: 33035382
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of Thymopoietin-Antisense RNA 1 as Long Noncoding RNA in the Pathogenesis of Human Cancers.
Zheng Q; Jia J; Zhou Z; Chu Q; Lian W; Chen Z
DNA Cell Biol; 2021 Jul; 40(7):848-857. PubMed ID: 34096793
[TBL] [Abstract][Full Text] [Related]
14. Promising long noncoding RNA DLX6-AS1 in malignant tumors.
Xue C; Lv L; Jiang J; Li L
Am J Transl Res; 2020; 12(12):7682-7692. PubMed ID: 33437353
[TBL] [Abstract][Full Text] [Related]
15. DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1.
Wu Q; Ma J; Meng W; Hui P
Cancer Biol Ther; 2020; 21(1):17-25. PubMed ID: 31591939
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DLX6-AS1 increases the expression of HIF-1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR-199a-5p.
Yang B; Jia L; Ren H; Jin C; Ren Q; Zhang H; Hu D; Zhang H; Hu L; Xie T
Mol Genet Genomic Med; 2020 Jan; 8(1):e1017. PubMed ID: 31782911
[TBL] [Abstract][Full Text] [Related]
17. Long Noncoding RNA
Xie F; Xie G; Sun Q
Cancer Biother Radiopharm; 2020 Mar; 35(2):129-136. PubMed ID: 32077747
[No Abstract] [Full Text] [Related]
18. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
Ding XZ; Zhang SQ; Deng XL; Qiang JH
Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
[TBL] [Abstract][Full Text] [Related]
19. Research progress of DLX6-AS1 in human cancers.
Luo Y; Ge P; Wang M; Chen H; Liu J; Wei T; Jiang Y; Qu J; Chen H
Hum Cell; 2021 Nov; 34(6):1642-1652. PubMed ID: 34508305
[TBL] [Abstract][Full Text] [Related]
20. DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA.
Hu C; Liu K; Wang B; Xu W; Lin Y; Yuan C
Curr Pharm Des; 2021; 27(9):1211-1218. PubMed ID: 33121401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
